LncRNA BCAN-AS1 stabilizes c-Myc via N 6 -methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer

Guandi Wu,Jiachun Su,Lingxing Zeng,Shuang Deng,Xudong Huang,Ying Ye,Rui Li,Ruihong Bai,Lisha Zhuang,Mei Li,Quanbo Zhou,Yanfen Zheng,Junge Deng,Shaoping Zhang,Rufu Chen,Dongxin Lin,Jialiang Zhang,Jian Zheng
DOI: https://doi.org/10.1038/s41418-023-01225-x
IF: 12.067
2023-09-20
Cell Death and Differentiation
Abstract:C-Myc overexpression contributes to multiple hallmarks of human cancer but directly targeting c-Myc is challenging. Identification of key factors involved in c-Myc dysregulation is of great significance to develop potential indirect targets for c-Myc. Herein, a collection of long non-coding RNAs (lncRNAs) interacted with c-Myc is detected in pancreatic ductal adenocarcinoma (PDAC) cells. Among them, lncRNA BCAN-AS1 is identified as the one with highest c-Myc binding enrichment. BCAN-AS1 was abnormally elevated in PDAC tumors and high BCAN-AS1 level was significantly associated with poor prognosis. Mechanistically, Smad nuclear-interacting protein 1 (SNIP1) was characterized as a new N 6 -methyladenosine (m 6 A) mediator binding to BCAN-AS1 via recognizing its m 6 A modification. m 6 A-modified BCAN-AS1 acts as a scaffold to facilitate the formation of a ternary complex together with c-Myc and SNIP1, thereby blocking S phase kinase-associated protein 2 (SKP2)-mediated c-Myc ubiquitination and degradation. Biologically, BCAN-AS1 promotes malignant phenotypes of PDAC in vitro and in vivo. Treatment of metastasis xenograft and patient-derived xenograft mouse models with in vivo-optimized antisense oligonucleotide of BCAN-AS1 effectively represses tumor growth and metastasis. These findings shed light on the pro-tumorigenic role of BCAN-AS1 and provide an innovant insight into c-Myc-interacted lncRNA in PDAC.
cell biology,biochemistry & molecular biology
What problem does this paper attempt to address?